PathogenDx technology provides simple, powerful, and inexpensive DNA Testing.
PathogenDx has developed the next generation “standard” for very large scale cannabis, botanical, food and agricultural testing: first to detect pathogens that are harmful to humans, and then, in a second product, an extension of the technology to also detect pathogens that are harmful to the plants. This will address the loss of billions of dollars in produce and crop in the supply chain from the time it leaves the grower/farmer until it reaches the retailer.
Raw Sample Genotyping (RSG), the first arm of the PathogenDx technology platform
RSG allows raw sample – whether it is leaf/produce washes, swabs or leaf/produce homogenate to be analyzed at the DNA level, for pathogens present within them, in a way that averts the need for (1) DNA purification, (2) DNA quantitation, and (3) DNA quality analysis. The elimination of these processes, that are currently required when employing Real-Time PCR (qPCR) testing, saves up to 20 steps, the cost of additional materials and much time and labor.
Samples are simply applied directly to the workflow after heat and enzyme treatment to disrupt the cell or spore wall. The workflow simplification that results from RSG will be a game changer in PathogenDx testing, by cutting the testing workflow in half and dramatically decreasing the time needed for sample preparation. PathogenDx’s RSG Intellectual property is protected by an awarded US patent in July 2014. Numerous international patents are pending.
Low Cost Microarray (LCM) – the second arm of the PathogenDx technology platform
LCM enables (1) a very inexpensive, (2) very simple process requiring minimal technician expertise, and (3) multiple pathogen detection and analysis all in one test. The testing format shown is a 12 well microarray, and can be produced up to a 48 well microarray. This simple but extremely powerful tool provides labs across the world to perform up to 12 to 48 tests in parallel analyzing 10-20 pathogens simultaneously.
Therefore, Based on LCM, it is now possible to perform quantitative DNA based testing, on panels of pathogens as large as 100, at a cost per test that is less than half that obtainable by standard DNA methods such as Real Time PCR (qPCR). LCM is supported by multiple awarded US and international patents.
Combining the power of these two technologies, licensed from GMSBiotech – RSG + LCM will allow a single technician to process more than a hundred samples per 8 hour shift: from leaf to data, to generate a DNA test panel that could grow from the present industry needs (about 10 pathogens in parallel) to what the industry will require in a decade (possibly 100 human pathogens and plant disease markers) all as a single test, where the cost and ease of use of 100 tests will be nearly identical to that for 10 tests.
For comparison using today’s Real-time PCR technology, a 100 sample leaf workflow, would require the following: DNA purification from 100 leaves, followed by DNA quantitation for all 100, and then Real Time PCR on 100 leaves x 10 tests (1000 PCRs) would require the work of two technicians at least two-three full days.